Starting today, GP surgeries across England will begin prescribing Mounjaro, a weekly injection designed to aid weight loss, but only for patients who meet stringent eligibility criteria. This cautious rollout by NHS England aims to prioritize those most in need, manage GP workloads, and ensure sustainable use of NHS resources.
Who Can Get Mounjaro From Their GP?
Currently, only people with severe obesity and multiple related health conditions qualify. Eligible patients must have:
A Body Mass Index (BMI) of 40 or above (or 37.5 for individuals from minority ethnic backgrounds),
Plus at least four of these five conditions: type 2 diabetes, high blood pressure, heart and vascular disease, high cholesterol, and obstructive sleep apnoea.
Patients prescribed Mounjaro will also receive comprehensive support, including guidance on exercise and healthy eating, ensuring a holistic approach to weight management.
Why the Strict Approach?
NHS England emphasizes a phased rollout to focus on those at greatest health risk while allowing time for GPs to receive necessary training and manage the additional workload. Mounjaro requires monthly monitoring during the initial treatment phase, making it resource-intensive.
Some GP practices have already advised patients who do not meet the criteria not to book appointments regarding Mounjaro at this stage. Alternative weight loss support, such as workshops and digital apps, remains available.
How Does Mounjaro Work?
Mounjaro (tirzepatide) was originally approved to treat type 2 diabetes but has shown remarkable results in weight loss by reducing appetite and increasing feelings of fullness. Clinical trials have demonstrated an average weight loss of around 20% of body weight in users.
Availability and Demand Challenges
While Mounjaro is now accessible through some GP surgeries and community clinics, supply may not meet demand immediately. The Company Chemists’ Association warns that many eligible patients might face waiting periods due to limited availability and the need for trained healthcare staff.
Certain groups, including pregnant or breastfeeding women and those with specific medical histories like pancreatitis or thyroid tumors, are advised against using Mounjaro.
Future Expansion Plans
NHS England plans to widen access gradually:
By June 2026, eligibility may extend to people with a BMI between 35 and 39.9 with four qualifying conditions.
By April 2027, those with a BMI of 40 and three qualifying conditions might also become eligible.
Over the next 12 years, an estimated 3.4 million people in England could benefit from Mounjaro under NHS care, pending ongoing evaluation by health authorities.
Availability Across the UK
In Wales, Mounjaro is currently available through specialist NHS weight management clinics, with potential expansion to primary care under review.
Northern Ireland is developing a regional obesity management service that will include medication options.
Scotland has limited NHS prescribing of weight loss drugs, with decisions made regionally by health boards.
Practical Advice for Patients
Dr. Claire Fuller, NHS England’s co-national medical director for primary care, encourages anyone concerned about their weight and health to discuss all available NHS support options with their healthcare provider. Weight loss injections like Mounjaro are one tool among many, and lifestyle changes remain a cornerstone of effective obesity management.
Related topics:
